

Bivalent Boosters Creating Adverse Childhood Experiences in Kids Ages 5-11

Injections that Evoke Symptoms Our Children Will not Forget

By Dr. Peter McCullough

Global Research, January 23, 2023

Courageous Discourse

Theme: Science and Medicine

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), click here.

Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

We often remember events from our childhood that came from physical experiences such as a broken arm or falling into a stream. Most patients from yesteryear remember childhood rheumatic or scarlet fever. Parents bringing their children age 5-11 years for COVID-19 vaccination may be creating adverse childhood experiences based on the most recent CDC safety data published by Hause et al in MMWR.

Morbidity and Mortality Weekly Report

US Department of Health and Human Services/Centers for Disease Control and Prevention

MMWR / January 13, 2023 / Vol. 72 / No. 2

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023

Anne M. Hause, PhD^1 ; Paige Marquez, $MSPH^1$; Bicheng Zhang, MS^1 ; John R. Su, MD, PhD^1 ; Tanya R. Myers, PhD^1 ; Julianne Gee, MPH^1 ; Sarada S. Panchanathan, MD^2 ; Deborah Thompson, MD^2 ; Tom T. Shimabukuro, MD^1 ; David K. Shay, MD^1

TABLE 2. Adverse reactions and health impacts reported to v-safe for children aged 5–11 years* who received a bivalent Pfizer-BioNTech or Moderna COVID-19 vaccine booster dose, by vaccine—United States, October 12–January 1, 2023

	No. (%) reporting reaction or health impact after vaccination§			
Event [†]	Pfizer-BioNTech (n = 2,647)	Moderna (n = 612)	Total (N = 3,259)	
Any injection site reaction	1,740 (65.7)	470 (76.8)	2,210 (67.8)	
Pain	1,683 (63.6)	463 (75.7)	2,146 (65.9)	
Swelling or hardness	229 (8.7)	64 (10.5)	293 (9.0)	
Redness	211 (8.0)	64 (10.5)	275 (8.4)	
Itching	123 (4.7)	21 (3.4)	144 (4.4)	
Any systemic reaction	1,215 (45.9)	379 (61.9)	1,594 (48.9)	
Fatigue	798 (30.2)	278 (45.4)	1,076 (33.0)	
Headache	534 (20.2)	211 (34.5)	745 (22.9)	
Fever	512 (19.3)	198 (32.4)	710 (21.8)	
Myalgia	353 (13.3)	145 (23.7)	498 (15.3)	
Chills	247 (9.3)	103 (16.8)	350 (10.7)	
Nausea	208 (7.9)	89 (14.5)	297 (9.1)	
Abdominal pain	182 (6.9)	56 (9.2)	238 (7.3)	
Vomiting	115 (4.3)	39 (6.4)	154 (4.7)	
Joint pain	106 (4.0)	41 (6.7)	147 (4.5)	
Diarrhea	74 (2.8)	15 (2.5)	89 (2.7)	
Rash	37 (1.4)	8 (1.3)	45 (1.4)	
Any health impact	506 (19.1)	196 (32.0)	702 (21.5)	
Unable to attend school	355 (13.4)	114 (18.6)	469 (14.4)	
Unable to perform normal daily activities	298 (11.3)	149 (24.4)	447 (13.7)	
Needed medical care	49 (1.9)	13 (2.1)	62 (1.9)	
Outpatient clinic	30 (1.1)	7 (1.1)	37 (1.1)	
Telehealth	10 (0.4)	4 (0.7)	14 (0.4)	
Other	12 (0.5)	3 (0.5)	15 (0.5)	
Emergency department	4 (0.1)	0 (—)	4 (0.1)	
Hospitalization	0(—)	0(—)	0(—)	

TABLE 3. Events* reported to the Vaccine Adverse Event Reporting System for children aged 5-11 years¹ after receipt of a bivalent Pfizer-Bio/Mzch or Moderna COVID-19 vaccine booster dose — United States, October 12–November 20, 2022

	No. (%) reporting, by vaccine			
Adverse events	Pfizer- BioNTech (n = 847)	Moderna (n = 75)	Total (N = 922)	
Serious reports§				
Total serious reports	2 (0.2)	0 (—)	2 (0.2)	
Nonserious reports				
Total nonserious reports	845 (99.8)	75 (100)	920 (99.8)	
Reports of vaccination error	726 (85.9)	49 (65.3)	775 (84.2)	
Error without adverse health event	661 (91.0)	40 (81.6)	701 (90.5)	
Error with adverse health event**	65 (9.0)	9 (18.4)	74 (9.5)	
Reports not specifying vaccination error ^{††}	119 (14.1)	26 (34.7)	145 (15.8)	
Fever	13 (10.9)	8 (30.8)	21 (14.5)	
Syncope	17 (14.3)	3 (11.5)	20 (13.8)	
Vomiting	10 (8.4)	8 (30.8)	18 (12.4)	
Nausea	12 (10.1)	5 (19.2)	17 (11.7)	
Dizziness	12 (10.1)	2 (7.7)	14 (9.7)	
Fall	11 (9.2)	1 (3.9)	12 (8.3)	
Fatigue	6 (5.0)	5 (19.2)	11 (7.6)	
Headache	5 (4.2)	6 (23.1)	11 (7.6)	
Loss of consciousness	11 (9.2)	0 (—)	11 (7.6)	
Cough	7 (5.9)	2 (7.7)	9 (6.21)	
Urticaria	7 (5.9)	2 (7.7)	9 (6.21)	



Hause AM, Marquez P, Zhang B, Su JR, Myers TR, Gee J, Panchanathan SS, Thompson D, Shimabukuro TT, Shay DK. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years – United States, October 12-January 1, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39-43. doi: 10.15585/mmwr.mm7202a5. PMID: 36634021.

Moderna, which had greater frequency of adverse events than Pfizer, for example, caused 30% of children to have fever and vomit. Combined, 22% reported that boosters had a negative health impact, 14% could not perform daily activities to return to school, and 2% were so sick they required acute medical care. Adverse childhood experiences can have lasting social and psychological ramifications later in life, particularly if they are repeated. No vaccine, no matter how theoretically compelling, should be in public use with these symptomatic side effects. Vaccines should have acceptable safety profiles with <5% having any significant short-term symptoms, be safe over the long term, provide at least 50% protection against a disease, inhibit transmission, and last at least a year. Faulty vaccines that underperform or make our kids sick should be rejected by parents and removed from the market to protect public safety.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Sources

Hause AM, Marquez P, Zhang B, Su JR, Myers TR, Gee J, Panchanathan SS, Thompson D, Shimabukuro TT, Shay DK. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years – United States, October 12-January 1, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39-43. doi: 10.15585/mmwr.mm7202a5. PMID: 36634021.

O'Shea BQ, Demakakos P, Cadar D, Kobayashi LC. Adverse Childhood Experiences and Rate of Memory Decline From Mid to Later Life: Evidence From the English Longitudinal Study of Ageing. Am J Epidemiol. 2021 Jul 1;190(7):1294-1305. doi: 10.1093/aje/kwab019. PMID: 33534903; PMCID: PMC8484774.

Featured image is from Mercola

The Worldwide Corona Crisis, Global Coup d'Etat Against

Humanity

by Michel Chossudovsky

by Michel Chossudovsky

les by Peter

ccullough

Michel Chossudovsky reviews in detail how this insidious project "destroys people's lives". He provides a comprehensive analysis of everything you need to know about the "pandemic" — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

"My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the "deadly" COVID-19 "vaccine". This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument."

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: \$11.50 Get yours for FREE! Click here to download.

We encourage you to support the eBook project by making a donation through Global Research's <u>DonorBox "Worldwide Corona Crisis" Campaign Page</u>.

The original source of this article is <u>Courageous Discourse</u> Copyright © <u>Dr. Peter McCullough</u>, <u>Courageous Discourse</u>, 2023

CORONA CRISIS

CORONA CRISIS

Corona Corona

Disclan. The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are

acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca